Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
09/08/2022 - 08:00 AM
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022, both virtually and in-person at the Lotte New York Palace Hotel.
The presentation may be accessed from the H.C. Wainwright platform or from the Events & Presentations page in the Investors section on the Company’s website. A replay of the presentation will be accessible for 90 days.
In addition, if you are interested in arranging a virtual 1x1 meeting with members of the Crinetics management team, please contact your bank/conference representative.
About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine , a somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in Phase 1 clinical studies for CRN04777 , an investigational, oral somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, and for CRN04894 , an investigational, oral ACTH antagonist for the treatment of Cushing’s disease, congenital adrenal hyperplasia, and other diseases of excess ACTH. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.
Contacts: Chas Schultz VP, IR & Corporate Communications cschultz@crinetics.com (858) 450-6464
Investors / Media: Corey Davis LifeSci Advisors, LLC cdavis@lifesciadvisors.com (212) 915-2577
Aline Sherwood Scienta Communications asherwood@scientapr.com (312) 238-8957
Crinetics Pharmaceuticals Inc
CRNX Rankings
#359 Ranked by Stock Gains
CRNX Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Pharmaceuticals: Major
Country
United States
City
San Diego
About CRNX
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.